# Phase 2, Randomized, Double-Blind, Placebo-Controlled of the Efficacy and Safety of CF102 in Hepatocellular Carcinoma (HCC)

> **NCT02128958** · PHASE2 · COMPLETED · sponsor: **Can-Fite BioPharma** · enrollment: 78 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** CF102
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02128958
- **Lead sponsor:** Can-Fite BioPharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09
- **Primary completion:** 2017-11-27
- **Final completion:** 2021-12-31
- **Target enrollment:** 78 (ACTUAL)
- **Last updated:** 2022-10-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02128958

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02128958, "Phase 2, Randomized, Double-Blind, Placebo-Controlled of the Efficacy and Safety of CF102 in Hepatocellular Carcinoma (HCC)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02128958. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*